Zimmer Biomet Holdings, Inc.
NYSE:ZBH · New York Stock Exchange
+$0.87 today
Vol 1.59M · Avg 2.28M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
5.6%
avg 4.6%
ROIC
5.5%
avg 3.3%
ROA
3.1%
avg 2.4%
Analysis
ROE is currently the strongest return metric at 5.6% versus its period average of 4.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Ivan Tornos | President, Chief Executive Officer & Chairman of the Board | $4.11M | — | 51 | $78,602.00 | 0.04% |
JehanZeb Noor | Senior VP, Chief Strategy, Business Development, Innovation & Transformation Officer | $2.56M | — | 44 | $5,151.00 | <0.01% |
Suketu Upadhyay | Chief Financial Officer and Executive Vice President of Finance, Operations & Supply Chain | $2.21M | — | 57 | $71,514.00 | 0.04% |
Wilfred van Zuilen | Group President of Europe, Middle East & Africa | $1.59M | — | 56 | $31,553.00 | 0.02% |
Chad F. Phipps | Senior VP, Chief Legal & Corporate Affairs Officer and Secretary | $1.32M | — | 54 | $68,603.00 | 0.04% |
Kevin R. Thornal | Group President of Global Businesses & Americas | $1.32M | — | 52 | $27,385.00 | 0.01% |
Jonathan Vigdorchik | Chief Science, Technology & Medical Affairs Officer | — | — | — | — | — |
David DeMartino | Senior Vice President of Investor Relations | — | — | — | — | — |
Paul A. Stellato | Interim CFO, VP, Controller & Chief Accounting Officer | — | — | 51 | $9,098.00 | <0.01% |
Shaun Braun | Senior Vice President & Chief Information and Technology Officer | — | — | — | — | — |
Angela Main | Senior Vice President, Global Chief Compliance Officer & Associate General Counsel of Asia Pacific | — | — | — | — | — |
Kristen Cardillo | Senior Vice President & Chief Communications Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
7
$1.19M
Net Sentiment
$1.19M
Net selling
Most Active
Yi Sang
4 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 7 sells worth $1.19M over the last 12 months. That adds up to net selling of $1.19M. Yi Sang was the most active insider with 4 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -60.7% | +28.4% (15yr)6 analysts |
| Revenue | N/A | N/A | +10.3% | +3.4% (15yr)9 analysts |
| Net Income | N/A | N/A | -42.0% | +19.8% (15yr)9 analysts |
| EBIT | N/A | N/A | -23.6% | +7.1% (15yr)9 analysts |
Analysis
Recent growth has been strongest in Revenue at +10.3% over three years. Forward estimates point to EPS at +28.4% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
DexCom, Inc.
NASDAQ:DXCM
$27.95B
Illumina, Inc.
NASDAQ:ILMN
$24.50B
West Pharmaceutical Services, Inc.
NYSE:WST
$23.17B
Waters Corporation
NYSE:WAT
$23.17B
United Therapeutics Corporation
NASDAQ:UTHR
$22.76B
Quest Diagnostics Incorporated
NYSE:DGX
$21.58B
Labcorp Holdings Inc.
NYSE:LH
$20.98B
STERIS plc
NYSE:STE
$19.74B
Incyte Corporation
NASDAQ:INCY
$19.62B
Smith & Nephew plc
NYSE:SNN
$12.74B
Who manages ZBH?
Zimmer Biomet Holdings, Inc. (ZBH) lists 12 active executives. The top listed executive is Jonathan Vigdorchik, Chief Science, Technology & Medical Affairs Officer.
Are ZBH insiders buying or selling?
Recent insider activity shows net selling of $5.89M.
Explore More
Continue the stock analysis
Jump to another research area for this company.